Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of ...

A recent study published in The Lancet highlighted the potential of AI-driven cardiac imaging to identify under-diagnosed cardiomyopathies earlier than ever before. Artificial intelligence (AI) ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

The growth of the Medical Laser Market is driven by rise in prevalence of chronic diseases, and high adoption of medical lasers by healthc ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...

Optimism…is the obstinacy of maintaining that everything is best when it is worst.” – Voltaire, Candide You, Governor Polis, ...

Fewer than half of heart patients from 17 countries who could benefit from beneficial drugs are taking them, researchers ...

A new study has identified an enzyme that plays an important role in breaking down unneeded or damaged proteins in the heart -- an important process for maintaining heart health.